计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
KX2-391 (Tirbanibulin) 是第一个临床Src抑制剂(拟肽类),靶向作用于Src的肽底物位点,在癌细胞系中GI50为9-60 nM。KX2-391 是一种高选择性的Src 激酶抑制剂,IC50值为20 nM 。
KX2-391 是一种非ATP 竞争性Src抑制剂。KX2-391是第一种靶向Src激酶底物结合位点的抑制剂。KX2-391 抑制Src 催化的FAK、Shc、paxillin转磷酸化以及Src 激酶自磷酸化。KX2-391 对PDGFR、EGFR、JAK1、JAK2 和Lck 没有影响,证明其为选择性抑制剂。KX2-391还是一种微管蛋白聚合抑制剂,通过与异二聚体微管蛋白上特定的位点结合而起抑制作用。在细胞实验中,KX2-391在NIH3T3/c-Src527F和SYF/c-Src527F 细胞中显示出生长抑制作用,GI50 值分别为23 nM 和39 nM 。
由于Src 是细胞增殖、存活、迁移和侵袭的调节因子,KX2-391 针对各种实体瘤和许多白血病肿瘤是有效的。已经证实KX2-391抑制原发性肿瘤生长并抑制肿瘤转移。
Information
KX2-391 (Tirbanibulin) KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
In vitro
KX2-391 is a Src inhibitor that is directed to the Src substrate pocket. KX2-391 shows steep dose-response curves against Huh7 (GI 50 = 9 nM), PLC/PRF/5 (GI 50 = 13 nM), Hep3B (GI 50 = 26 nM), and HepG2 (GI 50 = 60 nM), four hepatic cell cancer (HCC) cell lines. KX2-391 is found to inhibit certain leukemia cells that are resistant to current commercially available drugs, such as those derived from chronic leukemia cells with the T3151 mutation. KX2-391 is evaluated in engineered Src driven cell growth assays inNIH3T3/c-Src527F and SYF/c-Src527F cells and exhibits GI50 with 23 nM and 39 nM, respectively.
In vivo
In pre-clinical animal models of cancer, orally administered KX2-391 is shown to inhibit primary tumor growth and to suppress metastasis.
Cell Data
cell lines:
Concentrations:6,564 to 0.012 nM
Incubation Time:3 days
Powder Purity:≥99%
| ALogP | 2.9 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | K408930 |